• About us
• Contact

Advertisement

Organisation › Details

Vico Therapeutics B.V.

Vico Therapeutics is a clinical-stage genetic medicines company developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe neurological diseases. Our lead product candidate, VO659, is currently in Phase 1/2a clinical development for the treatment of spinocerebellar ataxia types 3 and 1 and Huntington’s disease and is the only ASO in the clinic that targets the underlying CAG repeat expansions that cause all nine known polyglutamine diseases. Vico’s research platform designs fit-for-purpose ASOs by applying precision chemistry with mechanisms of action ideally suited to target genetic neurological diseases. *

 

	Start	2019-10-25 established (s-off)
	Industry	BIOTECH
	Industry 2	Antisense OligoNucleotides technology (AON technology)
	Person	Mackison, Micah (Vico Therapeutics 202208– CEO before Locanabio 202012 CBO)
	Person 2	Dochez, Luc (Vico Therapeutics 202007 CEO + Co-Founder + Droia Genetic Disease Fund Managing Partner before Prosensa)
	Region	Leiden
	Country	Netherlands
	Street	21 J.H. Oortweg BioScience Park Leiden, BioPartner Building 1
	City	2333 CH Leiden
	Tel	+31-71-2036800
		Address record changed: 2024-09-15
Basic data	Employees	n. a.
		* Document for »About Section«: Vico Therapeutics B.V.. (1/5/24). "Press Release: Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline". Leiden.
		Record changed: 2024-09-15

Advertisement

More documents for Vico Therapeutics B.V.

• [1] Vico Therapeutics B.V.. (1/5/24). "Press Release: Vico Therapeutics Announces $60 million (€54 million) Series B Financing to Advance VO659 Clinical-Stage Program for Rare Neurological Diseases and Expand Pipeline". Leiden....
• [2] Vico Therapeutics B.V.. (6/29/21). "Press Release: US FDA Grants Vico Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia". Leiden....
• [3] Vico Therapeutics B.V.. (2/10/21). "Press Release: European Commission Grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia". Leiden....
• [4] Vico Therapeutics B.V.. (10/1/20). "Press Release: Dutch Vico Therapeutics Strengthens Leadership Team with the Appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent Director". Leiden....
• [5] Vico Therapeutics B.V.. (7/29/20). "Press Release: Biotech Vico Therapeutics Raises $31 Million (€27 Million) in Series A Financing Round to Advance Therapies for Rare Central Nervous System Diseases". Leiden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.